Tag: RNVA

Blue Horseshoe Stocks: Options, Bottom-Plays & More

New Options Ideas

After a relatively subdued half-day to close out the short week on Friday, we’re going to wipe the slate and start fresh today with a couple of options ideas. Based off of our initial scans and the premarket activity, we think each of these plays has the potential to help us start the week on a high note.

AngloGold Ashanti Ltd. AU – For this one, we’re attracted to the positioning on the chart, where, as you can see below, the stock has just begun to rebound off of its lowest PPS in roughly 9 months. Add that to some bullish premarket activity, along with a number of ripening indicators, and we’re very interested in the possibilities.

We’re going to be focusing in on the AU 1/20 $11 and $12 Calls, which gives us more than enough time to see the extended recovery we’re looking for.


_____

Cognizant Technology Solutions Corp. CTSH – Our interest was roused by CTSH in this morning’s routine scan, and it too is currently in a favorable position on the chart, coupled with an appreciable premarket gap-up which could lead to a strong session performance.

For this one, we’re going to be looking at the CTSH Weekly $57-60 Calls.

Lithium Exploration Group, Inc. LEXG

Here we have another prime bottom-play with LEXG, which has managed to put together a pretty good rebound off of 6-month lows over the past few sessions.

Currently trading at a low multiple around .0025, we’re looking at a stock that ran from similar levels to over .02 back in August. Even a fraction of such a move from current PPS levels would equate to sizable gain opportunities, so we’ll be putting LEXG on watch in the days and weeks ahead.


_____

CollabRx, Inc. RNVA – This one belongs in the bottom-bouncer category as well. RNVA is coming off of its recently established 52-week low, and appears to be geared up for a continued comeback. We’re going to have this one on close watch as well.

All-Cannabis Extended Watchlist:
AMMJ, TRTC, MJNA, MCOA, CNBX, HEMP, VAPE, AGTK, MJTK

Blue Horseshoe Stocks: Options, Bottom-Plays & More

MarilynJean Interactive, Inc. MJMI

We want to circle back around to a play we tagged for observation last week. MJMI has been making a good deal of progress, showing upward momentum over the past couple of sessions.

Subsequent to our mention of the stock we took note of a .091 low (Friday), and after a couple days on the upswing, MJMI reached a high of .216 yesterday afternoon. It represents a three session-swing amounting to 137%

We’ll want to see the stock maintain support at or above the 50DMA at .16 on any pullbacks in order to remain interested.

Potential Momentum Plays

Each of the following stocks represents the possibility for continued momentum coming into this morning’s sessions. Both closed just a shade under their respective highs-of-day, and will be placed on watch as we cruise through midweek.

CollabRx, Inc. RNVA – We’re no strangers to this stock, which is in the midst of filling a sizable gap on the chart that presently runs from current PPS levels in the mid-to-upper .30’s, on up to around .47.

Yesterday RNVA hit a high of .39 before closing just below at .37. We’re looking for the stock to produce its fourth consecutive session of higher highs and higher lows today.
______

Intermolecular, Inc. IMI – IMI is new to our reports this morning, and qualifies as both a bottom-bouncer as well as a potential momo-play. It also ended up closing with strength, just a hair shy of its daily high yesterday.

It comes less than a week removed from a big PPS dropoff, so we’ll be on the lookout for the stock to continue this rebound and regain some of the ground it has lost over the past week or so.

Tempur Sealy International, Inc. TPX – Options Update

We also want to provide a quick update on the TPX longer-term options idea that we’ve been tracking for over a week now. We were initially interested in the TPX 08/19 $70-80 Calls. The $70’s have since been pushed too deep in the money, but over the past week both the $75’s and $80’s have performed quite well:

$75 Calls – Range: 1.91-4.50 – Max Gain: 135%
$80 Calls – Range: .38-1.35 – Max Gain: 255%

We’ll continue to track these plays leading into their expiration next Friday.

Extended Watchlist:
ECPN, MINE, EEGI, ASPS, PLG, JD

Blue Horseshoe Stocks: Updates, Fresh Plays & More

Kraig Biocraft Laboratories, Inc. KBLB

We alerted KBLB in Wednesday morning’s premarket report, and on that day, we would observe a PPS low of .0261. Yesterday, the stock hit a high of .0395, for a respectable two-session upswing of 51%

Following that solid run-up, we saw the stock close at .0375, maintaining a vast majority of its advance. We’ll continue to keep a steady eye on KBLB, and look for it to maintain support above the .03-mark in order to keep us interested.

Potential Bottom-Plays

Rennova Health, Inc. RNVA – We have an interesting story unfolding with RNVA, and a potential rebound opportunity as well. After briefly cracking its 50DMA on Wednesday, the stock took a major gut punch yesterday as it gapped down immensely.

It seems a bit of an overreaction after reading the PR that apparently catalyzed the selloff. The company announced yesterday that it had priced a public offering with the intent of raising upwards of $8.6M in capital, expected to close by Tuesday. They set the purchase price at .45, which is why a massive slide to less than .30 seemed disproportionate.

We’ll be interested to see the activity in this now majorly-oversold stock in sessions to come.


__________

Ampio Pharmaceuticals, Inc. AMPE – Speaking of stocks that have recently gapped down hard and found new lows, we have AMPE hitting our bottom-play radar.

Similar to the aforementioned play, the selloff occurred as a result of what some might construe as over-reactive. The company released data from a clinical study at the end of last month on its osteoarthritis injection treatment that was poorly-received.  However, while the primary endpoints of the double-blind study were not met, the treatment was markedly effective in improving the patients with the most extreme cases of the condition.

So the study was not a total loss, and the company made clear its intent to submit an FDA application for the treatment for those severely afflicted patients that were helped, and for whom no other non-surgical alternative exists.

That’s why we’ll be keeping an eye on AMPE to continue to regain some of its lost ground, as it has done over the past few sessions.

Extended Watchlist:
MAXD, MFST, PPHM, FES, SPU, KURA, COSI(Bottom watch)